MedTrace Logo

A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies

NCT01705847 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2016-05-17

No results posted yet for this study

Summary

This study is to determine the appropriate dosing regimen of GS-9820 in subjects with lymphoid malignancies. This is a Phase 1b, open-label, dose-escalation and expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of GS-9820.

Conditions

  • Lymphoid Malignancies

Interventions

DRUG

GS-9820

GS-9820 tablets containing 200 mg of GS-9820 administered orally

Sponsors & Collaborators

Principal Investigators

  • Henry Adewoye, MD · Gilead Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2016-05-31
Completion
2016-05-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01705847 on ClinicalTrials.gov